Survival of breast cancer patients in tripoli

Jamahiriya Medical Journal

Volumn 9, Issue 2, 2009, Pages 144-147

  El Habbash, Manal ^a   Alwindi, Abukris ^b  

^a Tripoli Medical Centre   (Libyan Arab Jamahiriya)

^b UNIVERSITY OF TRIPOLI   (Libyan Arab Jamahiriya)

Author keywords

Breast; Cancer; Survival; Tripoli

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN; METHOTREXATE; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MENOPAUSE; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PLEURA METASTASIS; PREMENOPAUSE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; VISCERAL METASTASIS;

EID: 77953469099     PISSN: 20791216     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Timothy J.Key, Naomi E. Allen, Elizabeth A. Spencer, Ruth C. Travis. Nutrition and breast cancer. The breast (2003)12:412-416.
2. Daniel F. Hayes, prognostic and predictive factors revisited .The Breast (2005) 14,493-499.
3. Schiff R,SAW F. The importance of the oestrogen receptor in breast cancer. In: JR P, ed. Breast cancer: prognosis, treatment, and prevention. New York, Basel: Marcel Dekker, Inc., 2002:149-186.
4. Miller BA, Kolonel LN, Bernstein: Racial ethanic patterns of cancer in United State 1988-1992. Bethesda, MD National Cancer Institute, 1996.
5. Ries L A G, Eisner M P, Kosary C L et al. SEER Cancer Statistics Review, 1973-1999.Bethesda, MD: National Cancer Institute, 2002.
6. Park J.E. zaheer M., Hekmat Kadry Ali .family health, Short text book on community medicine Al-Fath university.1982, 183.
7. Jack Cuzick , Epidemiology of breast cancer. The breast (2003)12:405-411.
8. Goldhirsch A, Glick J H, Gelber R D, Coates A S, senn H J. Meeting highlights: international consensus Panel on the treatment of primary breast Cancer: seventh international conference on Adjuvant therapy of primary breast cancer. J Clin Oncol 2001;19:3817-3827.
9. Marco C, Nicole R, Giulia P et al. Size of breast cancer metastases in Axillary lymph nodes : clinical relevance of minimal lymph node involvement. J Clin Oncol 2005;vol23;No:7:1379-1389.
10. Miguel P, Ivo A. Olivotto, Caroline H. Speers, et al, Evolving Treatment Strategies for Inflammatory Breast Cancer: A population-based Survival Analysis J ClinOncol 2005;vol 23:No:9; 1941-1949.
11. Benz C C, Scott G K, Sarup J C Johnson R M, et al. oestrogen dependent, Tamoxifen - resistant tumorigenic growth of MCF-7 cell transfected with HER2/neu. Breast Cancer Res Treatment 1993; 24:85-95.
12. C. Kent Osborne, Rachel Schiff, Grazia Arpino, et al. Endocrine responsiveness: Understanding how progesterone receptor can be use to select endocrine therapy. The Breast (2005)14:458-465.
13. Bendell JC, Domchek SM , Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972-7.
14. Harry Bartelink. Radiotherapy to the conserved breast, chest wall, and regional nodes: is there standard? The breast. (2003)12:475-482.
15. th international conference, St. Gallen, Switzerland abstract book, 2003; Poster no. 5 page S18.